中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

26 records (took 0.016 seconds)

    TRANSFECTED T-CELLS AND T-CELL RECEPTORS FOR USE IN IMMUNOTHERAPY AGAINST CANCERS
    4.
    发明申请
    TRANSFECTED T-CELLS AND T-CELL RECEPTORS FOR USE IN IMMUNOTHERAPY AGAINST CANCERS 审中-公开

    公开(公告)号：US20200339652A1

    公开(公告)日：2020-10-29

    申请号：US16813248

    申请日：2020-03-09

    Applicant: IMMATICS BIOTECHNOLOGIES GMBH

    Inventor： Dominik MAURER ,  Sebastian BUNK ,  Leonie ALTEN

    IPC: C07K14/725 ,  A61K35/12 ,  A61K35/17 ,  A61K35/66 ,  C07K14/435 ,  C12N15/09 ,  C12N15/10

    Abstract: Disclosed are T-cell receptors (TCRs) binding to tumor-associated antigens (TAAs) for targeting cancer cells, T-cells expressing same, methods for producing same, and methods for treating cancers using same. Disclosed are TCRs and their variants that bind to HLA class I or II molecules with a peptide, such as MAG-003 have the amino acid sequence of KVLEHVVRV (SEQ ID NO:1). The description further relates to peptides, proteins, nucleic acids, cells for use in immunotherapeutic methods, the immunotherapy of cancer, and tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

    TRANSFECTED T-CELLS AND T-CELL RECEPTORS FOR USE IN IMMUNOTHERAPY AGAINST CANCERS
    7.
    发明申请
    TRANSFECTED T-CELLS AND T-CELL RECEPTORS FOR USE IN IMMUNOTHERAPY AGAINST CANCERS 有权

    公开(公告)号：US20210101956A1

    公开(公告)日：2021-04-08

    申请号：US17125922

    申请日：2020-12-17

    Applicant: IMMATICS BIOTECHNOLOGIES GMBH

    Inventor： Dominik MAURER ,  Sebastian BUNK ,  Leonie ALTEN

    IPC: C07K14/725 ,  A61K35/12 ,  A61K35/17 ,  A61K35/66 ,  C07K14/435 ,  C12N15/09 ,  C12N15/10

    Abstract: Disclosed are T-cell receptors (TCRs) binding to tumor-associated antigens (TAAs) for targeting cancer cells, T-cells expressing same, methods for producing same, and methods for treating cancers using same. Disclosed are TCRs and their variants that bind to HLA class I or II molecules with a peptide, such as MAG-003 have the amino acid sequence of KVLEHVVRV (SEQ ID NO:1). The description further relates to peptides, proteins, nucleic acids, cells for use in immunotherapeutic methods, the immunotherapy of cancer, and tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

    T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME AGAINST PRAME POSITIVE CANCERS
    9.
    发明申请
    T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME AGAINST PRAME POSITIVE CANCERS 审中-公开

    公开(公告)号：US20190256572A1

    公开(公告)日：2019-08-22

    申请号：US16403038

    申请日：2019-05-03

    Applicant: Immatics Biotechnologies GmbH

    Inventor： Leonie ALTEN ,  Dominik MAURER ,  Sebastian BUNK ,  Claudia WAGNER ,  Mathias FERBER

    IPC: C07K14/725 ,  C07K16/30

    Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular against Preferentially Expressed Antigen of Melanoma (PRAME). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

Patent Agency Ranking